Kaoru Shimada

TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement

Filipa C. Lynce, Kaoru Shimada, Claudine J. Isaacs, Xue Geng et autres

PARP inhibitors (PARPi) drive efficacy in BRCA-mutant breast cancer (BC) via DNA damage-induced synthetic lethality and immune activation, supporting their combination with immune checkpoint blockade. In the TALAVE study, patients with advanced BRCA-mutant or wild-type (WT) HER2-negative BC received talazoparib followed by …

us (code pays fourni par la source)

Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial

Emily Chen, Ilana Schlam, Kaoru Shimada, Tianyu Li et autres

Given the heterogeneity of HER2-positive breast cancer, reliable biomarkers to guide treatment are needed. We conducted multi-platform biomarker analyses of baseline tumor tissue from the DAPHNe trial of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) for HER2-positive early breast cancer to characterize inter- and intra-tumor heterogeneity …

us, br, il (code pays fourni par la source)

Multicenter prospective EN-MARK study: efficacy of third-line trastuzumab deruxtecan and dynamic changes in biomarkers, including HER2 status

Akira Ooki, H. Osumi, Kaoru Shimada, Naoko Machida et autres

Background Human epidermal growth factor receptor 2 (HER2) is overexpressed in ∼20% of advanced gastroesophageal adenocarcinomas (GEAs). Trastuzumab (T-mab) is the standard first-line treatment for HER2-positive GEA, and trastuzumab deruxtecan (T-DXd) has demonstrated clinical efficacy in later-line settings. However, the potential loss …

jp (code pays fourni par la source)

APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer

Carlos Wagner S Wanderley, Daniel E. Michaud, Kaoru Shimada, Adam Nelson et autres

Novel anti-HER2 antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd), have shown efficacy in tumors with varying HER2 expression, including HER2-low and even tumors with minimal HER2 presence. This has sparked interest in the biology underlying the HER2 expression spectrum. Using molecular …

us, br (code pays fourni par la source)

Instance-Based Discovery of ItemSBs Leveraging Individuality Through Discretization

Yasuhiro Suzuki, Kaoru Shimada

This study proposes a novel instance-based method for discovering itemsets with statistically distinctive backgrounds (ItemSBs) by discretizing continuous attribute values. Instead of discretizing an entire dataset, in this method, each instance's continuous attributes are discretized individually using Standard Deviation-Based Discretization and Segmented …

jp (code pays fourni par la source)

An Estrogen Receptor Signaling Transcriptional Program Linked to Immune Evasion in Human Hormone Receptor-Positive Breast Cancer

Kaoru Shimada, Daniel E. Michaud, Yvonne Xiaoyong Cui, Kelly Zheng et autres

us (code pays fourni par la source)

Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment

Takafumi Tsushima, Nobue Sato, Yong‐Mei Guo, Hirotaka Nakamura et autres

The incidence of Richter transformation in relapsed/refractory chronic lymphocytic leukemia (CLL) is up to 15% and Richter transformation is a frequent cause of treatment failure on ibrutinib (IBR) [1]. IBR has been promising in CLL cell growth suppression by inhibiting Bruton tyrosine …

jp (code pays fourni par la source)

TRPV4 channels promote vascular permeability in retinal vascular disease

Anri Nishinaka, Miruto Tanaka, Kentaro Ohara, Eiji Sugaru et autres

jp (code pays fourni par la source)

Evaluation of a simultaneous adsorption device for cytokines and platelet–neutrophil complexes in vitro and in a rabbit acute lung injury model

Yumiko Sekiya, Kaoru Shimada, Hiroshi G. Takahashi, Chisa Kuga et autres

Abstract Background Platelet–neutrophil complexes (PNCs) readily migrate into tissues and induce tissue damage via cytokine or other pathogenic factors release. These actions are involved in onset and progression of acute respiratory distress syndrome (ARDS). Thus, simultaneous removal of cytokines and activated neutrophils, …

us, jp (code pays fourni par la source)

Evaluation of A Simultaneous Adsorption Device For Cytokines And Neutrophil-Platelet Complexes In Vitro And In A Lung-Protective Ventilated Rabbit Acute Lung Injury Model

Yumiko Sekiya, Kaoru Shimada, Hiroshi G. Takahashi, Chisa Kuga et autres

Abstract Background: Neutrophil-platelet complexes (NPCs) readily migrate into tissues and induce tissue damage via cytokine or other pathogenic factors release. These actions are involved in onset and progression of acute respiratory distress syndrome (ARDS). Thus, simultaneous removal of cytokines and activated neutrophils …

us, jp (code pays fourni par la source)

Publisher Correction: Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation

Jui–Hsia Weng, Peter David Koch, Harding H. Luan, Ho-Chou Tu et autres

us (code pays fourni par la source)

Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation

Jui–Hsia Weng, Peter David Koch, Harding H. Luan, Ho-Chou Tu et autres

us (code pays fourni par la source)